Autolus Therapeutics cuts about 13% of staff, targets $15 million in annual savings

Autolus Therapeutics plc (Nasdaq: AUTL) announced on April 29, 2026, a plan to improve operational efficiency and cut operating expenses. The company is implementing a reduction in force affecting about 13% of its workforce across all areas of the business. The release, datelined London and Gaithersburg, Maryland, says the initiative is focused on gross profit margin and a path to profitability for its acute lymphoblastic leukemia business.

The business behind the cuts

Autolus describes itself as a commercial-stage biopharmaceutical company developing T cell therapies. Its marketed product, AUCATZYL (obecabtagene autoleucel, also known as obe-cel), was approved by the FDA in November 2024 for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The U.S. launch and first sale followed in January 2025. The company's annual report filed on March 27, 2026, also lists a UK conditional marketing authorization in April 2025, a European Commission authorization in July 2025, and a recommendation from the National Institute for Health and Care Excellence in November 2025 for NHS use in England and Wales for adults aged 26 and older. The company launched the product in the United Kingdom in January 2026, where it is available through routine NHS commissioning.

The release also names three clinical programs: CATULUS, a pivotal Phase 2 trial in pediatric relapsed or refractory acute lymphoblastic leukemia; LUMINA, a pivotal Phase 2 trial in lupus nephritis; and BOBCAT, an exploratory Phase 1 trial in progressive multiple sclerosis. The company says those programs are on track. The release reports no new clinical data.

The cuts, the savings and the timing

The actions are expected to reduce operating expenses by about $15 million on an annualized basis, beginning in 2027. Restructuring charges are expected to total about $8 million, mostly employee severance and related costs, with the majority recognized in the first half of 2026. That total includes employee actions taken beginning in the second half of 2025. The company expects the workforce reduction to be substantially complete by the third quarter of 2026.

The company also says it will double manufacturing of products for commercial and clinical trial patients during 2026, even while headcount falls. The release reiterates full-year 2026 AUCATZYL net product revenue of $120 million to $135 million, up from $74 million in 2025, and an expected shift to positive gross margin in 2026. Chief Executive Officer Christian Itin is quoted in the release describing the cuts as a way to optimize the operating model. The release ties the $15 million figure to 2027, not to 2026.

The money

The annual report shows a net loss of $287.5 million for 2025, up from $220.7 million in 2024. Cash used in operations was $283.6 million in 2025, against $206.3 million in 2024. Research and development expense fell to $117.7 million in 2025 from $138.4 million in 2024. Revenue for 2024 was $10.1 million.

At the end of 2024, the annual report shows cash and cash equivalents of $227.4 million and short-term investments of $360.6 million. The release does not state the company's cash balance at a current date. It says only that, based on current operating plans and anticipated AUCATZYL net revenues, cash, cash equivalents and marketable securities are expected to be sufficient to fund operations into the fourth quarter of 2027.

The release does not say whether the company plans further workforce reductions, new financing or changes to its trial timelines.

Report an error

Companies in this story

AUTLAutolus Therapeutics plcNASDAQ · United KingdomOpen the starter desk